Compare Pfizer Inc (PFE) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Pfizer Inc trades at $28.21 (market cap $158.56B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Pfizer Inc is far larger — about 18.7× Global X NASDAQ 100 Covered Call ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals.
| PFE | QYLD | |
|---|---|---|
Market Cap | $158.56B | $8.49B |
Volume | 44,138,282 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $29.02 | $18.68 |
52-Week Low | $23.67 | $16.70 |
Typical Hold Time | 158 Days | — |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
QYLD trades at $18.675, down slightly by 0.03% on the day. The ETF shows a bullish technical signal from moving averages but bearish oscillators, with RSI levels indicating potential overbought conditions. Recent dividend payments of $0.18 per share were distributed monthly, supporting its income-focused strategy. News coverage highlights its high yield but also raises concerns about long-term capital erosion and capped upside.
The outlook for QYLD is mixed; it offers attractive monthly income but faces headwinds from declining option premiums and limited growth potential. Risks include principal erosion and tax implications, making it suitable for income-seeking investors who prioritize cash flow over capital appreciation. Analyst sentiment varies, with some upgrades citing yield attractiveness amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
